Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

Last updated: May 22, 2025
Sponsor: Ethicon, Inc.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Urinary Incontinence

Enuresis

Treatment

Intervention

Clinical Study ID

NCT04829357
ESC_2020_04
  • Ages > 21
  • Female

Study Summary

The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT ABBREVO® Continence System in women undergoing Mid-urethral sling surgery for Stress Urinary Incontinence (SUI).

Eligibility Criteria

Inclusion

Inclusion Criteria:

Subjects who satisfy all of the following criteria will be considered eligible for enrollment in this study:

  1. Stress urinary incontinence symptoms

  2. Diagnostic evaluation, a positive cough stress rest, to confirm diagnosis of stress urinary incontinence.

  3. Female subjects ≥ 21 years of age requiring treatment of SUI

  4. Desired surgical correction of stress urinary incontinence using synthetic sub-urethral vaginal slings

  5. Planned surgery for primary stress incontinence without concomitant prolapse surgery

  6. Patient able and willing to participate in follow-up

  7. Subject or authorized representative has signed the approved informed consent

Exclusion Criteria

Subjects meeting any of the following criteria will be considered not eligible for enrollment in this study:

  1. Physical or psychological condition which would impair study participation or are unwilling or unable to participate in all required study visits and are unable to complete the questionnaires

  2. Any pre-operative or intra-operative findings identified by the surgeon that may preclude the use of study product

  3. History of previous synthetic, biologic or fascial sub-urethral sling

  4. Pregnancy or plans for future pregnancy

  5. History of bleeding diathesis or current anti-coagulation therapy which cannot be suspended peri-operatively according to site's standard practice.

  6. Current genitourinary fistula or urethral diverticulum

  7. Reversible cause of incontinence (i.e. drug effect)

  8. Contraindication to surgery

Study Design

Total Participants: 195
Treatment Group(s): 1
Primary Treatment: Intervention
Phase:
Study Start date:
September 09, 2021
Estimated Completion Date:
February 27, 2037

Connect with a study center

  • General University Hospital

    Prague,
    Czechia

    Site Not Available

  • Bio-Medical University Rome

    Rome,
    Italy

    Active - Recruiting

  • Ospedale San Pietro Fatebenefratelli

    Rome,
    Italy

    Active - Recruiting

  • Zelazna Medical Center

    Warsaw,
    Poland

    Site Not Available

  • Ospedale Regionale Beata Vergine

    Mendrisio,
    Switzerland

    Active - Recruiting

  • Mercy Health

    Ada, Michigan 49301
    United States

    Site Not Available

  • Institute for Female Pelvic Medicine

    North Wales, Pennsylvania 19454
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.